2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science Announces Preliminary Results of Its Survey of Cannabis Use By Veterans and Others With Post Traumatic Stress Disorder (PTSD) "Listen to What Our Veterans Are Telling Us"

Cannabis Science Announces Preliminary Results of Its Survey of Cannabis Use By Veterans and Others With Post Traumatic Stress Disorder (PTSD) "Listen to What Our Veterans Are Telling Us"

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

The survey was designed and conducted by Mitch Earleywine, Ph.D. Professor of Psychology at the State University of New York (Albany). Dr Earleywine is also a member of the Cannabis Science Inc. Scientific Advisory Board. The survey results will be made public as soon as the study has been completed.

Dr. Robert Melamede, Cannabis Science President and CEO, observed, "It is clear that many veterans are already using herbal cannabis to self-medicate to relieve the symptoms of PTSD. Consequently, there is a clear need for standardized, FDA approved, oral cannabis products which can, and should be, provided to veterans and others who can benefit from its use. Medical cannabis has far fewer and milder side effects than most currently prescribed pharmaceutical products do. We are working hard to have one or more products ready for FDA clinical trials as soon as possible."

Dr. Melamede added, "It is shameful that the very people who have risked their lives and sacrificed their health to defend our freedoms have to break the law and risk their own freedom to use a safe medicine that they find to be most effective for relieving their suffering due PTSD. When we say that Cannabis Science Inc is a 'patient-oriented company', we really mean it. We are helping to educate Americans about their endocannabinoid system. It's time for Americans to speak out and listen to what our veterans and other citizens are telling us. Cannabis is medicine regardless of what some politicians say. Our goal is to provide quality assured, FDA approved cannabis extract medicines in pharmacies in every state in the union, and to have the medicine paid for by government and private healthcare plans. I believe cannabis medicines are the solution to our healthcare crisis"

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.